GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » SCYNEXIS Inc (LTS:0L49) » Definitions » Debt-to-Revenue

SCYNEXIS (LTS:0L49) Debt-to-Revenue : 0.52 (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is SCYNEXIS Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

SCYNEXIS's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.4 Mil. SCYNEXIS's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $2.5 Mil. SCYNEXIS's annualized Revenue for the quarter that ended in Mar. 2024 was $5.5 Mil. SCYNEXIS's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 was 0.52.


SCYNEXIS Debt-to-Revenue Historical Data

The historical data trend for SCYNEXIS's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SCYNEXIS Debt-to-Revenue Chart

SCYNEXIS Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 123.01 N/A 3.31 9.55 0.11

SCYNEXIS Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.88 0.03 2.10 0.65 0.52

Competitive Comparison of SCYNEXIS's Debt-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, SCYNEXIS's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SCYNEXIS's Debt-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, SCYNEXIS's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where SCYNEXIS's Debt-to-Revenue falls into.



SCYNEXIS Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

SCYNEXIS's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0.34 + 14.74) / 140.141
=0.11

SCYNEXIS's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0.356 + 2.487) / 5.492
=0.52

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Mar. 2024) Revenue data.


SCYNEXIS Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of SCYNEXIS's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


SCYNEXIS (LTS:0L49) Business Description

Traded in Other Exchanges
Address
1 Evertrust Plaza, 13th Floor, Jersey City, NJ, USA, 07302 - 6548
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. It is engaged in developing a lead product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains.

SCYNEXIS (LTS:0L49) Headlines

No Headlines